← Eichor
Study identifier: NCT06688331 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody

Condition: Presymptomatic Diabetes Type 1 (Stage 1) · Diabetes Mellitus, Type I · Diabetes Mellitus, Type 1  ·  Sponsor: PolTREG S.A.

PhasePhase 2
Planned participants150
Who can joinAll sexes, 3 Years to 18 Years
Healthy volunteersNo

About this study

The main purpose of the study is to check: * Can therapy with a preparation of regulatory cells (Tregs lymphocytes) and/or an anti-CD20 antibody preparation (rituximab) be successfully used in children with pre-diabetes to treat or delay type 1 diabetes? * Is therapy with a preparation of regulatory cells (Tregs lymphocytes) and/or a preparation of antiCD20 antibodies (rituximab) safe for children with pre-diabetes, and what side effects may be associated with it? The study will include patients at high risk for type 1 diabetes whose laboratory tests have confirmed preserved normal/high insulin production. First (part 1 of the study), tests will be performed to determine the risk of the disease (determination of autoantibodies that characterize the autoimmune background). In order to confirm the effectiveness of the therapy, not all patients will receive the study treatment. The study will be a so-called blinded randomized trial. This means that in this trial, all participants will undergo the same study procedures, but the participant will be randomly assigned to one of four (4) groups that will receive different treatment regimens before entering the study. The participant will be randomly assigned to one of four groups: * Group I will receive a preparation of regulatory cells (Tregs lymphocytes) along with a preparation of antiCD20 antibodies, * Group II will receive a preparation of regulatory cells (Tregs lymphocytes) together with an inert substance (placebo) * Grou…

This description comes directly from the study's public registry record.

Talk to the study team

Marta Druch, Clinical Trial Director  ·  +48731471845  ·  m.druch@poltreg.com

Katarzyna Karpinska, Sr Clinical Trial Specialist  ·  +48537504486  ·  k.karpinska@poltreg.com

Always discuss trial participation with your own doctor first.

Locations (9)

Uniwersytecki Dzieciecy Szpital Kliniczny Im. L. Zamenhofa W BialymstokuBialystok, PolandRecruiting
Uniwersyteckie Centrum KliniczneGdansk, PolandRecruiting
Gornoslaskie Centrum Zdrowia Dziecka Im. Sw. Jana Pawla II Samodzielny Publiczny Szpital Kliniczny Nr 6 Slaskiego Uniwersytetu Medycznego W KatowicachKatowice, PolandNot Yet Recruiting
Uniwersytet Medyczny W LodziLodz, PolandRecruiting
Uniwersytecki Szpital Dzieciecy w LublinieLublin, PolandRecruiting
Uniwersytecki Szpital Kliniczny w OpoluOpole, PolandRecruiting
Centrum Medyczne Medyk Sp. z o.o. S.K.Rzeszów, PolandRecruiting
Pomorski Uniwersytet Medyczny w SzczecinieSzczecin, PolandRecruiting
Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego We WroclawiuWroclaw, PolandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06688331